Results 91 to 100 of about 179,015 (305)

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Autophagy-based antidepressants? [PDF]

open access: yesBrazilian Journal of Psychiatry, 2023
Flávio Kapczinski   +4 more
doaj   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou   +3 more
wiley   +1 more source

Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis

open access: yesTranslational Psychiatry
Objective Gastrointestinal adverse effects are the most commonly reported adverse effects associated with the use of antidepressants. While existing studies on the gastrointestinal effects of antidepressant medications offer valuable insights, there are ...
Sixiang Wen   +8 more
doaj   +1 more source

Antidepressants and smoking cessation

open access: yes, 1999
Antidepressants and smoking ...
Bernabei, Roberto   +2 more
core   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask   +6 more
wiley   +1 more source

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

open access: yesHepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman   +4 more
wiley   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire   +3 more
wiley   +1 more source

Associations between antidepressants and risk of suicidal behavior and violent crimes in personality disorder

open access: yesEuropean Psychiatry
Background Despite uncertain benefits, antidepressants are used in the management of personality disorders (PDs). We investigated the association between antidepressants and two adverse outcomes - suicidal behaviour and violent crimes - in individuals ...
Kimmo Herttua   +3 more
doaj   +1 more source

Environmental impact of antidepressants: Is a new prescription framework possible?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Antidepressants such as venlafaxine and sertraline pose high risks to water ecosystems. As depressive disorders and other mental health conditions become increasingly prevalent worldwide, prescription and environmental presence of these pharmaceuticals continue to rise. This study explores the practical viability of a new framework for prescribing
Matilde Bianconi   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy